The global market for Ophthalmic Pharmaceutical Drugs is estimated at US$79.6 Billion in 2023 and is projected to reach US$102.5 Billion by 2030, growing at a CAGR of 3.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the ophthalmic pharmaceutical drugs market is driven by several factors, including technological advancements in drug development and delivery systems that enhance treatment efficacy and patient compliance. The expanding geriatric population globally, which is more susceptible to chronic eye conditions, significantly contributes to the increasing demand for ophthalmic medications. Moreover, the global increase in chronic diseases such as diabetes, which are often associated with serious eye complications, also boosts the market growth.
Consumer behavior is shifting towards preferring advanced, less invasive treatment options that offer quicker recovery and fewer side effects, which in turn drives the adoption of innovative ophthalmic drugs. Lastly, governmental and non-governmental efforts to raise awareness about eye health and improve accessibility to ophthalmic treatments play crucial roles in the market expansion, ensuring a sustained demand for these vital medications.
The growth in the ophthalmic pharmaceutical drugs market is driven by several factors, including technological advancements in drug development and delivery systems that enhance treatment efficacy and patient compliance. The expanding geriatric population globally, which is more susceptible to chronic eye conditions, significantly contributes to the increasing demand for ophthalmic medications. Moreover, the global increase in chronic diseases such as diabetes, which are often associated with serious eye complications, also boosts the market growth.
Consumer behavior is shifting towards preferring advanced, less invasive treatment options that offer quicker recovery and fewer side effects, which in turn drives the adoption of innovative ophthalmic drugs. Lastly, governmental and non-governmental efforts to raise awareness about eye health and improve accessibility to ophthalmic treatments play crucial roles in the market expansion, ensuring a sustained demand for these vital medications.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Anti-VEGF Agents Drug Class segment, which is expected to reach US$34.3 Billion by 2030 with a CAGR of a 4.5%. The Anti-Glaucoma Drug Class segment is also set to grow at 2.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $21.5 Billion in 2023, and China, forecasted to grow at an impressive 6.5% CAGR to reach $21.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Ophthalmic Pharmaceutical Drugs Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Ophthalmic Pharmaceutical Drugs Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Ophthalmic Pharmaceutical Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Allergan PLC, Bayer AG, F. Hoffmann-La Roche AG, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 32 Featured):
- Allergan PLC
- Bayer AG
- F. Hoffmann-La Roche AG
- Johnson and Johnson Vision Care Inc
- Kyowa Kirin Co., Ltd
- Novartis International AG
- Pfizer, Inc.
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceuticals Co., Ltd.
- Shire PLC
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Ophthalmic Pharmaceutical Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
3. MARKET TRENDS & DRIVERS
- Advances in Drug Delivery Systems Propel Growth in Ophthalmic Pharmaceutical Drugs Market
- Increasing Prevalence of Eye Disorders Expands Addressable Market Opportunity
- Technological Innovations in Formulations Generate Demand for Advanced Ophthalmic Drugs
- Growth in Geriatric Population Drives Adoption of Ophthalmic Pharmaceuticals
- Rising Awareness of Eye Health Strengthens Business Case for Preventative Treatments
- Adoption of Biologics and Biosimilars Spurs Growth in Ophthalmic Drug Market
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Ophthalmic Pharmaceutical Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Anti-VEGF Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Anti-Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Anti-Inflammatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Anti-Allergy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 21: World Historic Review for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 22: World 16-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 24: World Historic Review for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 25: World 16-Year Perspective for Over-the-Counter Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
UNITED STATES
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 28: USA 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 29: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: USA 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
CANADA
- TABLE 32: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: Canada 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 35: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: Canada 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
JAPAN
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 38: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: Japan 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 41: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Japan 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
CHINA
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 44: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: China Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: China 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 47: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: China Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: China 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
EUROPE
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 50: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 53: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 58: Europe 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
FRANCE
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 59: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 60: France Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 61: France 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 62: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 63: France Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 64: France 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
GERMANY
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 65: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 66: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 67: Germany 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 68: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 70: Germany 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
ITALY
- TABLE 71: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 72: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 73: Italy 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 74: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 76: Italy 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 77: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 78: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 79: UK 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 80: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 82: UK 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
SPAIN
- TABLE 83: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 84: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 85: Spain 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 86: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 88: Spain 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
RUSSIA
- TABLE 89: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 90: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 91: Russia 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 92: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 94: Russia 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 96: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 97: Rest of Europe 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 100: Rest of Europe 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 103: Asia-Pacific 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 106: Asia-Pacific 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 109: Asia-Pacific 16-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2014, 2024 & 2030
AUSTRALIA
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
LATIN AMERICA
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
MIDDLE EAST
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
AFRICA
- Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allergan PLC
- Bayer AG
- F. Hoffmann-La Roche AG
- Johnson and Johnson Vision Care Inc
- Kyowa Kirin Co., Ltd
- Novartis International AG
- Pfizer, Inc.
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceuticals Co., Ltd.
- Shire PLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 122 |
Published | September 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 79.6 Billion |
Forecasted Market Value ( USD | $ 102.5 Billion |
Compound Annual Growth Rate | 3.7% |
Regions Covered | Global |